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Abstract 13C has become an important tracer isotope for
studies of intermediary metabolism. Information about relative
flux through pathways is encoded by the distribution of 13C
isotopomers in an intermediate pool such as glutamate. This
information is commonly decoded either by mass spectrometry or
by measuring relative multiplet areas in a 13C NMR spectrum.
We demonstrate here that groups of glutamate 13C isotopomers
may be quantified by indirect detection of protons in a 2D
HMQC-TOCSY NMR spectrum and that fitting of these data
to a metabolic model provides an identical measure of the 13C
fractional enrichment of acetyl-CoA and relative anaplerotic flux
to that given by direct 13C NMR analysis. The sensitivity gain
provided by HMQC-TOCSY spectroscopy will allow an
extension of 13C isotopomer analysis to tissue samples not
amenable to direct 13C detection (V10 mg soleus muscle) and to
tissue metabolites other than glutamate that are typically present
at lower concentrations.
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1. Introduction
13C NMR isotopomer analysis is a powerful tool for eval-
uating relative £uxes through biochemical pathways [1^4].
The substantial advantages o¡ered by the high information
content in a 13C NMR spectrum over other carbon tracer
methods can be implemented whenever metabolite concentra-
tions are high or the amount of tissue is not limited. Extension
of these methods to human samples [5] or small tissue samples
from mice [6], for example, will ultimately be limited by the
NMR insensitivity of 13C. One solution is to apply indirect
methods whereby the heteronucleus is detected via its spin
interactions with 1H [7,8]. Although these methods do provide
a gain in sensitivity, information about 13C isotopomer pop-
ulations that is normally derived from 13C multiplet areas is
typically lost. Numerous homonuclear [9^14] and heteronu-
clear [15^20] 2D NMR methods have been used to resolve,
assign, or quantify tissue metabolite resonances, but this
powerful type of experiment has not been applied to 13C iso-
topomer analysis. We describe here a method for 13C iso-
topomer analysis of tissue extracts using heteronuclear multi-
ple quantum coherence-total correlation (HMQC-TOCSY)
NMR spectroscopy [21^23]. The initial multiple quantum
HMQC sequence ¢lters out all protons not spin-coupled to
a 13C while addition of the TOCSY sequence distributes this
information to all protons and thereby allows for the detec-
tion of long-range as well as direct 1H-13C correlations. We
have found that this combined sequence provides di¡erent but
complimentary positional 13C isotopomer information which
can be incorporated into existing mathematical models of in-
termediary metabolism. We show here that cross-peaks areas
in a HMQC-TOCSY spectrum provides a readout of 13C frac-
tional enrichment of acetyl-CoA (FC2) and relative anaplerotic
£ux (y) and demonstrate that the technique may be used to
derive signi¢cant metabolic information from as little as 10
mg of muscle tissue.
2. Materials and methods
2.1. Heart perfusions
Rat hearts were rapidly excised from male Sprague-Dawley rats
after general anesthesia. Isolated hearts were perfused using conven-
tional Langendor¡ methods (retrograde) at 100 cm H2O with Krebs-
Henseleit bicarbonate bu¡er (KH) bubbled continuously with a 95/5
mixture of O2/CO2 at 37‡C. The bu¡er (300 ml recirculating volume)
contained 2 mM [2-13C]acetate as the only oxidizable substrate. After
30 min, hearts were freeze-clamped with aluminum tongs pre-cooled
in liquid nitrogen. In a separate experiment, sodium [2,4,6,8-
13C4]octanoate (30 mg dissolved in 200 Wl of water) was infused
into a live, anesthetized mouse for 30 min (1 mg/min). The animal
was then killed and one soleus muscle was removed and freeze-
clamped. All tissues were extracted with ice-cold perchloric acid, neu-
tralized with KOH, freeze-dried, and dissolved in 600 Wl of D2O for
NMR analyses. The pH of all extract samples was adjusted to 2.6^2.8
using HCl prior to 2D NMR analysis to simplify the 1H NMR spec-
tra of glutamate. By lowering the pH, the two H3 protons become
more equivalent, and the chemical shift di¡erence between H3 and H4
is increased, thus removing the overlap between 13C satellites.
2.2. NMR spectroscopy
HMQC-TOCSY and 13C NMR spectra were collected using 5 mm
inverse and 5 mm broadband probes, respectively, on either an 11.75
T or 14.1 T Unity INOVA spectrometer (Varian Instruments, Palo
Alto, CA). A TOCSY mixing time of 40 ms was used. The HMQC-
TOCSY spectra were acquired with 2048 points in F2 and 128 incre-
ments (ni = 64, phase arrayed) in F1. The spectral widths were chosen
so that a range of 4 ppm would be covered in the 1H dimension (1.5^
5.5 ppm) and 40 ppm (22^62 ppm) in the 13C dimension. The
2048U128 matrices were zero ¢lled to 4096U512 and multiplied by
gaussian functions in both dimensions before Fourier transformation.
Given that weighting functions applied to FIDs prior to transfor-
mation will a¡ect measured cross-peak volumes in 2D spectra, all
calibration standards and heart extracts were acquired and processed
using identical parameters so that a direct comparison of cross-peak
volumes could be made. Cross-peak volumes in the HMQC-TOCSY
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spectra were measured using Varian NMR software (Version 5.3b)
after de¢ning each cross-peak manually with a volume box that in-
cluded approximately 25^30% baseline in each spectral dimension
[24]. A comparison of volumes was made for di¡erent sizes of the
volume boxes. Providing that adequate baseline was included in the
contour map de¢ning the cross-peak, no signi¢cant di¡erences were
observed in the volumes measured by the ¢tting program for a wide
range of baseline percentages (20^100% relative to width of cross-
peak).
13C NMR spectra were acquired by using a 45‡ pulse, a 3 s repe-
tition time, and WALTZ-16 for broadband 1H decoupling. The FIDs
were multiplied by an exponential weighting function corresponding
to a LB = 0.5 Hz prior to transformation. 13C NMR multiplets were
deconvoluted using the Varian software and the line-¢tting subroutine
of the PC-based NMR software, NUTS (Acorn NMR, Fremont, CA).
2.3. Standard curves
Samples containing various, known amounts of [4-13C]- and [U-
13C5]glutamate were used to obtain normalization factors for all
cross-peak volumes in the HMQC-TOCSY spectra. A stock solution
containing V10 mM [4-13C]- and [U-13C5]glutamate, pH 2.75, was
prepared in 99.9% D2O also containing 300 mM NaCl (average ionic
strength measured experimentally in heart extracts). This solution was
diluted sequentially with a second 300 mM NaCl/D2O solution to
vary the isotopomer concentration over a range of concentrations
similar to those found in tissue extracts.
2.4. Sensitivity enhancement
The experimental gain in sensitivity provided by the 2D HMQC-
TOCSY experiment versus 1D direct 13C observe was estimated using
a mixture of glutamate 13C isotopomers isolated from tissue. A stand-
ard 1D 13C NMR spectrum was collected using the same acquisition
parameters described above and a 2D HMQC-TOCSY spectrum was
collected using the same total data collection time. Identical weighting
functions as described above for tissue samples were applied prior to
Fourier transformation. Average signal-to-noise was measured sepa-
rately for the glutamate C2, C3 and C4 resonances in the 1D spectrum
and for their respective 1H traces in the HMQC-TOCSY spectrum.
3. Results
An 2D HMQC-TOCSY NMR spectrum of a solution con-
taining an equimolar mixture of [4-13C]- and [U-13C]glutamate
is shown in Fig. 1. Unlike a conventional 1D 1H spectrum,
this 2D spectrum contains 13C isotopomer information be-
cause the cross-peaks correlate 13C enrichment at every pro-
tonated carbon, not just the directly bonded carbon. This is
illustrated by the three cross-peaks located at 31 ppm on the
13C axis (C4 resonance) and 3.85 ppm on the 1H axis (H2
resonance). This triad of cross-peaks consists of a singlet
(C4H2S) and a doublet (C4H2D) component. The C4H2S
cross-peak re£ects all isotopomers having a 13C at C4 but
not at C2 (i.e. [4-13C]glutamate), while C2H4D re£ects all
isotopomers having 13C at both C2 and C4 (i.e. [U-
13C5]glutamate). Thus, the ratio of these two cross-peak vol-
umes should re£ect the ratio of these two groups of isotopo-
mers. As shown below, the cross-peak volumes in any S/D
triad may be compared directly (no correction factors re-
quired), so for the equimolar mixture of [4-13C]- and [U-
13C5]glutamate used in this experiment, the C4H2S and
C4H2D cross-peak volumes were equal.
Before HMQC-TOCSY cross-peak volume data can be
used in a metabolic isotopomer analysis, one must verify
that the procedure is quantitative. Fig. 2 shows plots of
HMQC-TOCSY cross-peak volumes as a function of gluta-
mate isotopomer concentration, measured over a range typical
of that found in heart tissue extracts. This titration was per-
formed by diluting a sample initially containing 9.7 mM [U-
13C5]glutamate and 8.5 mM [4-13C]glutamate. Fig. 2a shows
that the cross-peak S and D volumes within any CxHy group
have identical slopes (i.e. slopes of C4H2D and C4H2S are
equal and slopes of C4H3D and C4H3S are equal) and hence
the C4H2S/C4H2D and C4H3S/C4H3D cross-peak volume
ratios can be used in a metabolic analysis without further
correction. This indicates that mixing of 1H magnetization
between H4 and either H2 or H3 is independent of 13C enrich-
ment at C2 or C3, respectively [25]. Although analogous titra-
tions were not performed using mixtures of [2-13C]-, [3-13C]-,
[2,4-13C2]-, [2,3-13C2]- or [3,4-13C2]glutamate (due to their
commercial unavailability), we assume that no signi¢cant iso-
topic e¡ect would be observed for any isotopomer since none
was observed for [U-13C5]glutamate, the species that should
have produced the largest isotope e¡ect. Fig. 2b shows that
volume comparisons between Ss or between Ds (C4H2S versus
C4H3S or C4H2D versus C4H3D, for example) cannot be
made without signi¢cant correction. This demonstrates, as
expected, that transfer of 1H magnetization between gluta-
mate protons is not equivalent [26]. However, once calibration
curves such as those shown have been determined for a par-
ticular set of NMR spectral acquisition conditions, these data
can be used to correct all S/S and D/D cross-peak volume
ratios in a HMQC-TOCSY spectrum of glutamate in any
tissue extract. This allows one to directly quantify groups of
13C isotopomers for use in a metabolic analysis.
1D 13C NMR and 2D HMQC-TOCSY spectra of an ex-
tract of a rat heart perfused to steady state with [2-13C]acetate
are compared in Fig. 3. Each spectrum contains di¡erent but
complimentary information about the population of 13C iso-
topomers in the sample. In the 13C spectrum, relative 13C
enrichment at each carbon is given by the resonance areas
(after appropriate correction for T1 and nOe di¡erences) while
enrichment at nearest-neighbor carbons is reported by the
one-bond 13C-13C multiplets within each resonance. We
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Fig. 1. A HMQC-TOCSY 2D NMR spectrum of an equimolar mix-
ture (1 mM) of [4-13C]- and [U-13C5]glutamate. The cross-peak dou-
blet components, CxHyD, are due to the uniformly labeled iso-
topomer, and the singlet components, CxHyS, are due to the singly
labeled isotopomer. The pH of the sample was 2.75.
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have previously shown [1] that the 13C fractional enrichment
of the methyl carbon (C2) of acetyl-CoA entering the citric
acid cycle (FC2) and anaplerosis (y) are reported in the 13C
spectrum as:
FC2  C4D34 C4=C3 1
y  C4=C331=2 2
where C4D34 is the area of the J34 doublet in C4 relative to
the total area of the C4 resonance while C4/C3 is the ratio of
total C4 to C3 resonance areas (the latter ratio may require a
correction factor, depending upon how the spectrum was col-
lected). For a group of ¢ve hearts perfused with [2-
13C]acetate, the multiplet and resonance area ratios reported
in the 13C NMR spectra indicate that FC2 = 0.93 þ 0.03 and
y = 0.04 þ 0.01, identical to previously published values [1,3].
This same metabolic information is also encoded in the
HMQC-TOCSY spectrum. As in the 13C spectrum, we de¢ne
the S and D cross-peak volumes as a fraction of total volume
within each CxHy group, i.e. C4H3S+C4H3D = 1. Such frac-
tional volumes may be used to evaluate the same metabolic
data as that described above for the 13C spectrum. The chance
that a molecule of oxaloacetate with 13C at C2 (the carbonyl
carbon) will condense with [2-13C]acetyl-CoA in the citric acid
cycle is simply FC2. Since oxaloacetate C2 translates into glu-
tamate C3 on each turn of the cycle, FC2 is determined by the
ratio of all glutamate isotopomers having 13C at both C3 and
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Fig. 3. 13C NMR (a) and HMQC-TOCSY (b) spectra of an extract
of a rat heart perfused to steady state with [2-13C]acetate. The spec-
tra were collected at 11.75 T using the same 600 Wl sample but at
di¡erent pH values (pH = 7.20 for 13C and 2.75 for HMQC-TOCSY).
The 1D 13C spectrum (a) was collected over 2.4 h while the 2D
HMQC-TOCSY spectrum (b) was collected over 24 min. The insets
in the 13C spectrum show expanded C3 and C4 resonances contain-
ing the multiplet information used in Eqs. 1 and 2 for a 13C iso-
topomer metabolic analysis. The highlighted triad of cross-peaks in
the HMQC-TOCSY spectrum (C4H3S+C4H3D = 1 and C3H4S+
C3H4D = 1) represent the volume elements used in Eqs. 3 and 4 to
perform a similar metabolic analysis.
Fig. 2. Plots of measured HMQC-TOCSY cross-peak volumes as a
function of glutamate isotopomer concentration. a: The plots dem-
onstrate equal slopes for C4H3D and C4H3S (410.3 þ 3.5 and
408.4 þ 2.8) and equal but di¡erent slopes for C4H2D and C4H2S
(121.5 þ 2.9 and 117.9 þ 1.8). b: The slopes of the plots refer to the
other doublet cross-peak components due to [U-13C5]glutamate:
C3H4D (462.3 þ 4.2); C4H4D (409.8 þ 3.1); C3H3D (315.6 þ 6.5);
C2H2D (234.4 þ 2.2); C3H2D (210.2 þ 3.0); C2H3D (190.2 þ 2.1);
C2H4D (186.7 þ 2.5). These may be used as correction factors for
HMQC-TOCSY spectra of extracts collected at 14.1 T, pH 2.6^2.8,
25‡C, and using the spectral acquisition conditions outlined in Sec-
tion 2. Four HMQC-TOCSY spectra were acquired for each mix-
ture in order to estimate changes in cross-peak volumes.
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C4 versus those having 13C at C3 but not C4. This is directly
reported in the HMQC-TOCSY spectrum because all gluta-
mate isotopomers having 13C at both C3 and C4 contribute to
the C3H4D cross-peak volume while all isotopomers having a
13C at C3 but not at C4 contribute to the C3H4S cross-peak
volume. It follows that:
FC2  C3H4D 3
The fraction of unenriched acetyl-CoA entering the cycle,
FC0, is obtained by the di¡erence 13FC2 or simply C3H4S.
This is a non-steady-state measurement of FC2 because iso-
topic steady state is not required for the relationship to be
valid; the only requirement is that enough 13C has entered the
C3 position of glutamate to allow detection by HMQC-
TOCSY with reasonable signal-to-noise. The advantages of
HMQC-TOCSY versus 13C NMR for the determination of
FC2 are twofold; ¢rst, only one experimental measurement is
necessary (compare Eqs. 1 and 3) and, second, the data do not
require correction for spectral acquisition conditions. A third,
less obvious advantage, is that FC2 can also be evaluated in
the same spectrum by the volume element, C2H4D, assuming
complete randomization of the C2 and C3 carbons of sym-
metrical four-carbon cycle intermediates. This may ¢nd use as
an alternative measure of FC2 in situations where C3H4D is
obscured by other metabolite resonances (C2H4D is in a more
open region of the 2D spectrum).
Anaplerosis is de¢ned as £ux of metabolites other than
acetyl-CoA through citric acid cycle pools relative to citric
acid cycle £ux (y = a/c). Since acetate can only be oxidized
by mammalian tissue and cannot enter the cycle as an ana-
plerotic substrate, no labeling of anaplerotic substrate is pos-
sible in hearts perfused with [2-13C]acetate. Given this meta-
bolic condition, anaplerosis is proportional to total 13C
enrichment of C4/total 13C enrichment of C3 (see Eq. 2). In
the 2D HMQC-TOCSY spectrum, this ratio is reported by the
total volume of the C4H3 triad/total volume of the C3H4
triad,
y  C4H3triad=C3H4triad31=2 4
where C4H3 triad = C4H3S+C4H3D and C3H4 triad =
C3H4S+C3H4D. Note that this volume ratio required correc-
tion (C3H4 = 1.13UC4H3) because data were obtained from
two di¡erent cross-peak volume elements. As usual, measure-
ment of y also requires that the tissue be at metabolic and
isotopic steady state. Using volume data from HMQC-
TOCSY spectra collected on ¢ve di¡erent hearts and Eqs. 3
and 4, FC2 = 0.94 þ 0.03 and y = 0.05 þ 0.02, both in good
agreement with the respective values determined by direct
13C analysis.
The comparison presented above shows that identical met-
abolic information can be derived from glutamate multiplet
areas in a 1D 13C NMR spectrum and from glutamate cross-
peak volumes in a 2D HMQC-TOCSY spectrum. For typical
perfused heart studies where tissue glutamate is not limiting,
the 2D method o¡ers no clear advantage over direct 13C ob-
serve. However, in situations where either 13C fractional en-
richment is low or total tissue glutamate (or other metabolite
of interest) is limited, the sensitivity gain o¡ered by HMQC-
TOCSY could become critical. By comparing signal-to-noise
ratios in 1D and 2D spectra collected over identical total
collection periods, we found that our experimental gain in
sensitivity was 5.8, 2.5, and 5.1 for glutamate C2, C3 and
C4, respectively. Presumably, C3 shows a lower gain in sensi-
tivity due to the chemical shift non-equivalence of the H3
protons. Nevertheless, a 5^6-fold increase in sensitivity should
allow an extension of 13C isotopomer methods to smaller
samples (a few mg of tissue) or to metabolites normally not
detected by direct 13C observe. To illustrate this point, the
HMQC-TOCSY spectrum of an extract of a single soleus
muscle (wet weight V10 mg) removed from a mouse after
infusion of [2,4,6,8-13C]octanoate is presented in Fig. 4. Glu-
tamate was not detected in the 13C NMR spectrum of this
sample after an overnight acquisition yet the glutamate cross-
peaks are easily distinguished in a HMQC-TOCSY spectrum.
Substitution of the cross-peak volume element, C3H4D, into
Eq. 3 gave a FC2 value of 83%, showing that a majority of the
acetyl-CoA oxidized by this muscle was derived from octa-
noate.
4. Discussion
Previous applications of 1H detect 2D NMR methods to
follow metabolism of a 13C-enriched substrate have most
often involved linear pathways where a single 13C isotopomer-
ic metabolic product is formed [16,20]. To our knowledge, this
report describes the ¢rst application of HMQC-TOCSY to
quantify groups of 13C isotopomers in a metabolic intermedi-
ate (glutamate) and to relate that data to metabolic parame-
ters of interest using simple analytical relationships. The frac-
tion of acetyl-CoA derived from [2-13C]acetate (FC2) and
relative anaplerotic £ux (y) determined by HMQC-TOCSY
were shown to be identical to those determined from 13C
multiplet areas in a 1D high resolution 13C NMR spectrum.
We have estimated that the sensitivity gain o¡ered by indi-
rect detection of glutamate isotopomers on our 600 MHz
system (using di¡erent probes, inverse versus broad-band,
for the two experiments) ranged from 2.5 to 5.8. The theoret-
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Fig. 4. HMQC-TOCSY spectrum collected at 14.1 T of an extract
of a single mouse soleus muscle (V10 mg wet weight) after an infu-
sion of sodium [2,4,6,8-13C]octanoate.
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ical maximum gain in sensitivity for this experiment has been
reported to be 32-fold [27], yet much lower enhancements
have been observed in practice. Novotny et al. [28], using a
1D spin-echo 1H observe 13C editing method, measured a 14-
fold increase in sensitivity for 1H observe over 13C observe for
detection of the methyl resonance of [2-13C]ethanol in rabbit
brain. Most recently, Willker and coworkers [29] compared
2D HMQC versus 1D 13C observe and reported an average
signal-to-noise enhancement factor of 2.5 for several metabo-
lites in cell extracts (values ranged from 0.5 to 14). The 5^6-
fold gain in sensitivity observed here for glutamate has al-
lowed us to extend 13C isotopomer methods to sample sizes
typically used in tissue biopsies. It also o¡ers the possibility of
performing a 13C isotopomer analysis of other intermediates
that are less abundant in most tissues (i.e. malate, succinate,
citrate, or K-ketoglutarate), thereby allowing incorporation of
isotopomer data from several citric acid cycle intermediates in
existing models of metabolic £ux [3^5].
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